Overview
BPC-157 is a laboratory-synthesized pentadecapeptide originating from a naturally occurring gastric protein complex referred to as Body Protection Compound (BPC). Composed of a precise 15–amino acid sequence, this peptide has been explored in preclinical research settings for its biochemical properties and molecular stability.
In controlled research environments, BPC-157 serves as a biochemical research tool for examining cellular movement, extracellular matrix interactions, angiogenesis-related signaling, oxidative stress responses, and cytoskeletal dynamics. All findings associated with this peptide are derived exclusively from in-vitro studies and animal-based research models.
Molecular & Biochemical Profile
Database Reference: PubChem
Amino Acid Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Chemical Formula: C₆₂H₉₈N₁₆O₂₂
Molecular Mass: 1,419.56 g/mol
PubChem Identifier: 108101
Structurally, BPC-157 is a linear peptide and does not contain disulfide bonds. Its high proline content contributes to a rigid molecular conformation and enhanced resistance to enzymatic degradation, supporting stability in aqueous laboratory conditions.
Research Use & Experimental Scope
BPC-157 is provided strictly for research purposes and has been utilized in controlled experimental investigations involving:
- Fibroblast activity, including proliferation and guided migration
- Endothelial cell development and angiogenic structure formation
- Extracellular matrix synthesis and remodeling processes
- Cytoskeletal arrangement and focal adhesion signaling pathways
- Modulation of oxidative stress biomarkers in animal studies
- Nitric oxide–related biochemical signaling mechanisms
All experimental applications are confined to non-clinical research frameworks focused on understanding fundamental biological processes.
Mechanistic & Signaling Pathways
Research-based mechanistic analyses suggest that BPC-157 influences signaling networks associated with cell motility and vascular organization. Experimental evidence indicates involvement with VEGFR2-linked signaling pathways and downstream nitric oxide–mediated molecular events.
Additional in-vitro research has demonstrated alterations in phosphorylation patterns of focal adhesion proteins, which play a role in cytoskeletal attachment and cellular migration. These findings support the peptide’s use as a research probe for studying cytoskeletal remodeling under controlled conditions.
Summary of Preclinical Investigations
Peer-reviewed preclinical studies have evaluated BPC-157 across a variety of experimental models. In rodent research systems, investigations have focused on vascular response, gastrointestinal tissue structure, and connective tissue adaptation under laboratory-controlled conditions.
Further studies utilizing avian and invertebrate models have examined peptide stability and tissue-level responses to stress, contributing to a broader understanding of conserved biological signaling pathways.
Relationship Between BPC-157 Concentration and Vascular Endothelial Cell Growth
Source: PubMed
Formulation & Quality Verification
BPC-157 is supplied as a lyophilized powder manufactured through solid-phase peptide synthesis. Each production batch is analytically assessed using high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to verify molecular identity and purity.
Supporting analytical documentation is provided to ensure consistency, accuracy, and reproducibility across laboratory research applications.
Scientific References
- Huang, T., et al. Preclinical evaluation of the gastric pentadecapeptide BPC-157 in alkali-induced wound models, including effects on cellular proliferation, migration, and angiogenic activity. Drug Design, Development and Therapy, 2015.
- Drmić, D., et al. Experimental assessment of BPC-157 in rat models of cecal perforation, with comparative analysis involving L-NAME and L-arginine. World Journal of Gastroenterology, December 2018.
- Amić, F., et al. Investigation of vascular bypass mechanisms and duodenal lesion response in rats treated with the stable pentadecapeptide BPC-157. World Journal of Gastroenterology, December 2018.
- Duzel, A., et al. Effects of BPC-157 on colitis and ischemia-reperfusion injury in rodent research models. World Journal of Gastroenterology, December 2017.
- Vukojević, J., et al. Insights into inferior vena cava ligation models in rats and the role of BPC-157 in vascular response. Vascular Pharmacology, 2018.
- Drmić, D., et al. Evaluation of gastrointestinal, hepatic, and neurological lesions induced by celecoxib in rats and modulation by BPC-157. World Journal of Gastroenterology, August 2017.
- Hsieh, M.-J., et al. Association of BPC-157–induced angiogenic activity with VEGFR2 signaling pathways in experimental systems. Journal of Molecular Medicine, 2017.
- Grabarević, Z., et al. Effects of BPC-157 on nitric oxide–mediated lesion models in avian research systems. Journal of Physiology (Paris), October 1997.
- Sikiric, P., et al. BPC-157 as a cytoprotective mediator: experimental observations in vascular recruitment and gastrointestinal tissue models. Current Pharmaceutical Design, 2018.
- Seiwerth, S., et al. Comparative analysis of BPC-157 and established angiogenic factors in tissue healing research models. Current Pharmaceutical Design, 2018.
Research Use Only (RUO) Disclaimer
All products offered on this website are intended exclusively for in-vitro laboratory research purposes. In-vitro studies are conducted outside of a living organism under controlled laboratory conditions.
These products are not pharmaceuticals, medical devices, or therapeutic agents and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, prevention, treatment, or cure of any disease or medical condition.
Administration or introduction of these products into humans or animals is strictly prohibited by law.
For Laboratory Research Use Only.
Not intended for human use, medical use, diagnostic use, or veterinary use.
